samedan logo
 
 
 
spacer
home > ebr > winter 2001 > the business model - bridging the gap between technology and economic value
PUBLICATIONS
European Biopharmaceutical Review

The Business Model - Bridging the Gap Between Technology and Economic Value

The goal of the biotech industry is to create actual treatments for unmet medical needs. Biotechnology start-ups must take technology to market through a venture shaped by a specific business model, whether explicitly considered or implicitly embodied in the act of innovation. The inherent value of a technology remains latent until it is commercialised in some way. Obviously, the extent to which its value is realised depends upon the manner in which that takes place. Thus, technology managers must expand their perspectives in order to find the right business model, or 'the architecture of revenue' in order to capture value.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Pieter van der Meer, Investment Director and Partner with the
Biotechnology Team at Gilde Investment Management in the Netherlands Pieter van der Meer is an Investment Director and Partner with the biotechnology team of the venture capital organisation, Gilde Investment Management in the Netherlands. Pieter studied at Leiden University, graduating in Bio-organic Synthesis. He worked as a Management Consultant with KPMG Management Consulting before joining Gilde in 1998. The biotechnology fund has a keen interest in applied genomics technologies such as proteomics, systems biology, structural bioinformatics and so on. Pieter also serves on the board ofseveral European early stage technology companies.

spacer
Pieter van der Meer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Thermo Fisher Scientific Adds Patterned Microchip-based Technology to Liquid Chromatography Portfolio

PHILADELPHIA – ASMS 2021 – (November 1, 2021) – Thermo Fisher Scientific, the world leader in serving science, today announced its acquisition of Belgium-based PharmaFluidics, the developer of the μPAC range of micro-chip-based chromatography column.
More info >>

White Papers

Environmental Factors in Data Centres

Dycem

In addition to temperature and humidity, there are many more constraints in the environment that increase failure rates, explains Emilio Sapiña of Secure Techincal Rooms.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement